1216 related articles for article (PubMed ID: 24939927)
41. Randomized Trial of Stents Versus Bypass Surgery for Left Main Coronary Artery Disease: 5-Year Outcomes of the PRECOMBAT Study.
Ahn JM; Roh JH; Kim YH; Park DW; Yun SC; Lee PH; Chang M; Park HW; Lee SW; Lee CW; Park SW; Choo SJ; Chung C; Lee J; Lim DS; Rha SW; Lee SG; Gwon HC; Kim HS; Chae IH; Jang Y; Jeong MH; Tahk SJ; Seung KB; Park SJ
J Am Coll Cardiol; 2015 May; 65(20):2198-206. PubMed ID: 25787197
[TBL] [Abstract][Full Text] [Related]
42. The prognostic utility of the SYNTAX score on 1-year outcomes after revascularization with zotarolimus- and everolimus-eluting stents: a substudy of the RESOLUTE All Comers Trial.
Garg S; Serruys PW; Silber S; Wykrzykowska J; van Geuns RJ; Richardt G; Buszman PE; Kelbæk H; van Boven AJ; Hofma SH; Linke A; Klauss V; Wijns W; Macaya C; Garot P; DiMario C; Manoharan G; Kornowski R; Ischinger T; Bartorelli A; Van Remortel E; Ronden J; Windecker S
JACC Cardiovasc Interv; 2011 Apr; 4(4):432-41. PubMed ID: 21511223
[TBL] [Abstract][Full Text] [Related]
43. Comparison of Outcome of Coronary Artery Bypass Grafting Versus Drug-Eluting Stent Implantation for Non-ST-Elevation Acute Coronary Syndrome.
Chang M; Lee CW; Ahn JM; Cavalcante R; Sotomi Y; Onuma Y; Han M; Park DW; Kang SJ; Lee SW; Kim YH; Park SW; Serruys PW; Park SJ
Am J Cardiol; 2017 Aug; 120(3):380-386. PubMed ID: 28595861
[TBL] [Abstract][Full Text] [Related]
44. Improved long-term survival for diabetic patients with surgical versus interventional revascularization.
Kurlansky P; Herbert M; Prince S; Mack MJ
Ann Thorac Surg; 2015 Apr; 99(4):1298-305. PubMed ID: 25686668
[TBL] [Abstract][Full Text] [Related]
45. Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trials.
Caixeta A; Lansky AJ; Serruys PW; Hermiller JB; Ruygrok P; Onuma Y; Gordon P; Yaqub M; Miquel-Hebert K; Veldhof S; Sood P; Su X; Jonnavithula L; Sudhir K; Stone GW;
JACC Cardiovasc Interv; 2010 Dec; 3(12):1220-8. PubMed ID: 21232715
[TBL] [Abstract][Full Text] [Related]
46. Percutaneous coronary intervention versus coronary bypass surgery in United States veterans with diabetes.
Kamalesh M; Sharp TG; Tang XC; Shunk K; Ward HB; Walsh J; King S; Colling C; Moritz T; Stroupe K; Reda D;
J Am Coll Cardiol; 2013 Feb; 61(8):808-16. PubMed ID: 23428214
[TBL] [Abstract][Full Text] [Related]
47. Randomized comparison of everolimus-eluting stent versus sirolimus-eluting stent implantation for de novo coronary artery disease in patients with diabetes mellitus (ESSENCE-DIABETES): results from the ESSENCE-DIABETES trial.
Kim WJ; Lee SW; Park SW; Kim YH; Yun SC; Lee JY; Park DW; Kang SJ; Lee CW; Lee JH; Choi SW; Seong IW; Lee BK; Lee NH; Cho YH; Shin WY; Lee SJ; Lee SW; Hyon MS; Bang DW; Park WJ; Kim HS; Chae JK; Lee K; Park HK; Park CB; Lee SG; Kim MK; Park KH; Choi YJ; Cheong SS; Yang TH; Jang JS; Her SH; Park SJ;
Circulation; 2011 Aug; 124(8):886-92. PubMed ID: 21810659
[TBL] [Abstract][Full Text] [Related]
48. Coronary artery bypass graft surgery versus percutaneous coronary intervention with drug-eluting stents for left main coronary artery disease: A meta-analysis of randomized trials.
Putzu A; Gallo M; Martino EA; Ferrari E; Pedrazzini G; Moccetti T; Cassina T
Int J Cardiol; 2017 Aug; 241():142-148. PubMed ID: 28438354
[TBL] [Abstract][Full Text] [Related]
49. Long-term forecasting and comparison of mortality in the Evaluation of the Xience Everolimus Eluting Stent vs. Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization (EXCEL) trial: prospective validation of the SYNTAX Score II.
Campos CM; van Klaveren D; Farooq V; Simonton CA; Kappetein AP; Sabik JF; Steyerberg EW; Stone GW; Serruys PW;
Eur Heart J; 2015 May; 36(20):1231-41. PubMed ID: 25583761
[TBL] [Abstract][Full Text] [Related]
50. Paclitaxel-eluting balloon versus everolimus-eluting stent for treatment of drug-eluting stent restenosis.
Almalla M; Schröder J; Pross V; Marx N; Hoffmann R
Catheter Cardiovasc Interv; 2014 May; 83(6):881-7. PubMed ID: 23765557
[TBL] [Abstract][Full Text] [Related]
51. Differential long-term outcomes of zotarolimus-eluting stents compared with sirolimus-eluting and paclitaxel-eluting stents in diabetic and nondiabetic patients: two-year subgroup analysis of the ZEST randomized trial.
Jang SJ; Park DW; Kim WJ; Kim YH; Yun SC; Kang SJ; Lee SW; Lee CW; Park SW; Park SJ
Catheter Cardiovasc Interv; 2013 Jun; 81(7):1106-14. PubMed ID: 22899589
[TBL] [Abstract][Full Text] [Related]
52. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials.
Bangalore S; Kumar S; Fusaro M; Amoroso N; Attubato MJ; Feit F; Bhatt DL; Slater J
Circulation; 2012 Jun; 125(23):2873-91. PubMed ID: 22586281
[TBL] [Abstract][Full Text] [Related]
53. Influence of diabetes mellitus on long-term outcomes of patients with unprotected left main coronary artery disease treated with either drug-eluting stents or coronary artery bypass grafting.
Yu X; He J; Luo Y; Yuan F; Song X; Gao Y; Li Q; Huang F; Gu C; Lv S; Chen F
Int Heart J; 2015; 56(1):43-8. PubMed ID: 25742942
[TBL] [Abstract][Full Text] [Related]
54. Cost-effectiveness of percutaneous coronary intervention with drug-eluting stents versus bypass surgery for patients with 3-vessel or left main coronary artery disease: final results from the Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) trial.
Cohen DJ; Osnabrugge RL; Magnuson EA; Wang K; Li H; Chinnakondepalli K; Pinto D; Abdallah MS; Vilain KA; Morice MC; Dawkins KD; Kappetein AP; Mohr FW; Serruys PW;
Circulation; 2014 Sep; 130(14):1146-57. PubMed ID: 25085960
[TBL] [Abstract][Full Text] [Related]
55. Management of acute coronary syndromes in patients with diabetes: implications of the FREEDOM trial.
Burgess SN; Mussap CJ; French JK
Clin Ther; 2013 Aug; 35(8):1069-75. PubMed ID: 23973040
[TBL] [Abstract][Full Text] [Related]
56. Impact of previous coronary artery bypass surgery on clinical outcome after percutaneous interventions with second generation drug-eluting stents in TWENTE trial and non-enrolled TWENTE registry.
Sen H; Lam MK; Tandjung K; Löwik MM; van Houwelingen KG; Stoel MG; Louwerenburg HW; de Man FH; Linssen GC; Grandjean JG; Doggen CJ; von Birgelen C
Int J Cardiol; 2014 Oct; 176(3):885-90. PubMed ID: 25168098
[TBL] [Abstract][Full Text] [Related]
57. Long-term outcomes after stenting versus coronary artery bypass grafting for unprotected left main coronary artery disease: 10-year results of bare-metal stents and 5-year results of drug-eluting stents from the ASAN-MAIN (ASAN Medical Center-Left MAIN Revascularization) Registry.
Park DW; Kim YH; Yun SC; Lee JY; Kim WJ; Kang SJ; Lee SW; Lee CW; Kim JJ; Choo SJ; Chung CH; Lee JW; Park SW; Park SJ
J Am Coll Cardiol; 2010 Oct; 56(17):1366-75. PubMed ID: 20946993
[TBL] [Abstract][Full Text] [Related]
58. Drug-eluting versus bare-metal stents in the treatment of patients with ST-segment elevation myocardial infarction.
Hannan EL; Racz M; Walford G; Holmes DR; Jones RH; Sharma S; Katz S; King SB
JACC Cardiovasc Interv; 2008 Apr; 1(2):129-35. PubMed ID: 19463290
[TBL] [Abstract][Full Text] [Related]
59. Randomized comparison of sirolimus-eluting and everolimus-eluting coronary stents in the treatment of total coronary occlusions: results from the chronic coronary occlusion treated by everolimus-eluting stent randomized trial.
Moreno R; García E; Teles R; Rumoroso JR; Cyrne Carvalho H; Goicolea FJ; Moreu J; Mauri J; Sabaté M; Mainar V; Patricio L; Valdés M; Fernández Vázquez F; Sánchez-Recalde A; Galeote G; Jimenez-Valero S; Almeida M; Lopez de Sa E; Calvo L; Plaza I; Lopez-Sendón JL; Martín JL;
Circ Cardiovasc Interv; 2013 Feb; 6(1):21-8. PubMed ID: 23403384
[TBL] [Abstract][Full Text] [Related]
60. Long-term clinical and economic analysis of the Endeavor zotarolimus-eluting stent versus the cypher sirolimus-eluting stent: 3-year results from the ENDEAVOR III trial (Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
Eisenstein EL; Leon MB; Kandzari DE; Mauri L; Edwards R; Kong DF; Cowper PA; Anstrom KJ;
JACC Cardiovasc Interv; 2009 Dec; 2(12):1199-207. PubMed ID: 20129546
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
